Makita Masujiro, Sakai Takehiko, Kataoka Akemi, Kitagawa Dai, Ogiya Akiko, Morizono Hidetomo, Miyagi Yumi, Iijima Kotaro, Kobayashi Kokoro, Kobayashi Takayuki, Fukada Ippei, Araki Kazuhiro, Takahashi Shunji, Ito Yoshinori, Gomi Naoya, Oguchi Masahiko, Kita Mizuho, Arai Masami, Akiyama Futoshi, Iwase Takuji
Department of Breast Surgical Oncology, Cancer Institute Hospital, 3-8-31 Ariake Koto-ku, Tokyo, 135-8550 Japan ; Department of Breast Surgery, Nippon Medical School Musashi Kosugi Hospital, 1-396 Kosugi-machi, Nakahara-ku, Kawasaki, Kanagawa 211-8533 Japan.
Department of Breast Surgical Oncology, Cancer Institute Hospital, 3-8-31 Ariake Koto-ku, Tokyo, 135-8550 Japan.
Springerplus. 2015 Jul 22;4:365. doi: 10.1186/s40064-015-1150-0. eCollection 2015.
There is a significant difference in the mean tumor size between very young breast cancer patients and their elder counterparts. A simple comparison may show obvious prognostic differences. We investigated the prognostic impact of age by reducing the influence of the tumor size, which is thought to be a confounding factor.
We investigated 1,880 consecutive pT1-4N0-3M0 breast cancer patients treated at less than 45 years of age between 1986 and 2002 and conducted a case-control study of breast cancer subjects less than 30 years of age. Each patient (Younger than 30) was matched with a corresponding control subject (Elder counterpart) based on an age 15 years above the patient's age, a similar tumor size and a status of being within 1 year after surgery. In addition, we assessed 47 patients with pregnancy-associated breast cancer (PABC). The levels of hormone receptors were measured using an enzyme immunoassay (EIA), and receptor-positive cases were divided into "weakly" and "strongly" positive groups based on the median value. Years from the last childbirth (YFLC) was categorized as "recent" and "past" at the time point of 8 years.
There were fewer past YFLC cases, more partial mastectomy cases, a higher rate of scirrhous carcinoma or solid-tubular carcinoma in the Younger than 30 group than in the Elder counterpart group. The rates of a PgR-negative status in the Younger than 30 and Elder counterpart groups were 45.1 and 29.9%, respectively, As for the relationship between the PgR-negative rate and YFLC, the rates of a PgR-negative status in the past YFLC, nulliparous, recent YFLC and PABC groups were 31.9, 37.7, 44.4 and 65.7%, respectively. On the other hand, the rates of strongly positive cases were 42.6, 30.2, 22.2 and 8.6%, respectively. The 10-year recurrence-free survival rates in the Younger than 30, Elder counterpart and PABC groups were 61.7, 65.6 and 54.1%, respectively. The differences between the groups were not significant. In a multivariate analysis, independent prognostic facers included the number of lymph node metastases (4-9, HR:3.388, 95% CI 1.363-8.425, p = 0.0086, over 10, HR: 6.714, 2.033-22.177, p = 0.0018), solid-tubular carcinoma (HR 3.348, 1.352-8.292, p = 0.0090), scirrhous carcinoma (HR 2.294, 1.013-5.197, p = 0.0465) and past YFLC (HR 0.422, 0.186-0.956, p = 0.0387). An age younger than 30 was not found to be an independent prognostic factor.
The prognosis of the very young women was the same as their elder counterparts with a matched tumor size, and age was not identified to be an independent prognostic factor according to the multivariate analysis. Recent childbirth probably influences the prognosis of patients younger than 30 years of age with breast cancer by lowering hormonal sensitivity.
非常年轻的乳腺癌患者与其年长患者之间的平均肿瘤大小存在显著差异。简单比较可能显示出明显的预后差异。我们通过减少被认为是混杂因素的肿瘤大小的影响,研究了年龄对预后的影响。
我们调查了1986年至2002年间接受治疗的1880例连续的年龄小于45岁的pT1 - 4N0 - 3M0乳腺癌患者,并对年龄小于30岁的乳腺癌患者进行了病例对照研究。每位年龄小于30岁的患者(年轻组)与一名相应的对照对象(年长组)进行匹配,匹配条件为年龄比患者大15岁、肿瘤大小相似且处于术后1年内。此外,我们评估了47例妊娠相关乳腺癌(PABC)患者。使用酶免疫测定法(EIA)测量激素受体水平,受体阳性病例根据中位数分为“弱阳性”和“强阳性”组。距最后一次分娩的年限(YFLC)在8年这个时间点被分为“近期”和“既往”。
年龄小于30岁组中既往YFLC病例较少,保乳手术病例较多,硬癌或实体管状癌的发生率高于年长组。年龄小于30岁组和年长组中孕激素受体(PgR)阴性状态的发生率分别为45.1%和29.9%。至于PgR阴性率与YFLC的关系,既往YFLC组、未生育组、近期YFLC组和PABC组中PgR阴性状态的发生率分别为31.9%、37.7%、44.4%和65.7%。另一方面,强阳性病例的发生率分别为42.6%、30.2%、22.2%和8.6%。年龄小于30岁组、年长组和PABC组的10年无复发生存率分别为61.7%、65.6%和54.1%。各组之间的差异不显著。在多变量分析中,独立的预后因素包括淋巴结转移数量(4 - 9个,风险比[HR]:3.388,95%置信区间[CI] 1.363 - 8.425,p = 0.0086;超过10个,HR:6.714,2.033 - 22.177,p = 0.0018)、实体管状癌(HR 3.348,1.352 - 8.292,p = 0.0090)、硬癌(HR 2.294,1.